4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $765,150 | +69.2% | 24,016 | +7.6% | 0.00% | – |
| Q4 2023 | $452,325 | +38.0% | 22,326 | -13.3% | 0.00% | – |
| Q3 2023 | $327,721 | -47.6% | 25,744 | -25.6% | 0.00% | -100.0% |
| Q2 2023 | $625,529 | +170.2% | 34,617 | +157.1% | 0.00% | – |
| Q1 2023 | $231,464 | +1052009.1% | 13,465 | +1346400.0% | 0.00% | – |
| Q4 2022 | $22 | -100.0% | 1 | -100.0% | 0.00% | – |
| Q3 2022 | $141,000 | +15.6% | 17,548 | +0.8% | 0.00% | – |
| Q2 2022 | $122,000 | -56.7% | 17,408 | -6.7% | 0.00% | – |
| Q1 2022 | $282,000 | -14.3% | 18,650 | +24.6% | 0.00% | – |
| Q4 2021 | $329,000 | +36.5% | 14,968 | +67.3% | 0.00% | – |
| Q3 2021 | $241,000 | – | 8,945 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |